RT Journal Article
SR Electronic
T1 Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.20.20108555
DO 10.1101/2020.05.20.20108555
A1 Sang Youl Rhee
A1 Jeongwoo Lee
A1 Hyewon Nam
A1 Dae-Sung Kyoung
A1 Dae Jung Kim
YR 2020
UL http://medrxiv.org/content/early/2020/05/23/2020.05.20.20108555.abstract
AB Background Dipeptidyl peptidase-4 inhibitor (DPP-4i) and renin–angiotensin system (RAS) blockade are reported to affect the clinical course of coronavirus disease 2019 (COVID-19) in patients with diabetes mellitus (DM). However, the effectiveness of these drugs in large populations is unclear.Subjects and Methods As of May 2020, data analysis was conducted on all subjects who could confirm their history of claims related to COVID-19 in the National Health Review and Assessment Service database in Korea. Using the COVID-19 and claims data of the past 5 years, we compared the short-term prognosis of COVID-19 infection according to the use of DPP-4i and RAS blockade.Results Totally, data of 67850 subjects were accessible. Of these, 5080 were confirmed COVID-19. Among these, 832 subjects with DM were selected for analysis in this study. Among the subjects, 263 (31.6%) and 327 (39.3%) were DPP-4i and RAS blockade users, respectively. Thirty-four subjects (4.09%) received intensive care or died. The adjusted odds ratio for severe treatment among DPP-4i users was 0.362 [95% confidence interval (CI), 0.135–0.971], and that for RAS blockade users was 0.599 (95% CI, 0.251–1.431). No synergy was observed for subjects using both drugs.Conclusion This population-based study suggests that DPP-4i is significantly associated with a better clinical outcome of patients with COVID-19. However, the effect of RAS blockade is not significant.Competing Interest StatementResearchers from a pharmaceutical company participated in this study (JL, HN, and D-SK). They are experts on claims data, and their institutions have not intentionally influenced the basic hypothesis of the study, analysis plan, result arrangement, result interpretation, and manuscript preparation. The researchers from other institutions have no conflict of interest to declare.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Kyung Hee University Hospital (no. KHUH 2020-04-067). The requirement for informed consent was waived by the institutional review board because de-identified information was used for the analyses.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCurrently, in Korea, medication usage data for the past 5 years for those who have claimed a confirmatory test of COVID-19 are managed as a separate database for research. To protect personal information, the export of raw data is strictly prohibited by law, and research is being performed in a way that provides de-identified results when researchers submit program codes for analysis. https://hira-covid19.net/